BP
TEVA icon

Ballentine Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Ballentine Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Buy
11,392
+1,473
+15% +$49.1K ﹤0.01% 668
2026
Q1 		$299K Buy
9,919
+528
+6% +$17K ﹤0.01% 743
2025
Q4 		$293K Buy
+9,391
New +$231K ﹤0.01% 728
2017
Q4 		– Sell
-14,865
Closed -$262K – 417
2017
Q3 		$262K Sell
14,865
-2,889
-16% -$65K 0.01% 296
2017
Q2 		$582K Buy
+17,754
New +$550K 0.04% 178

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Ballentine Partners's TEVA Position: Q2 2026 in Review

Ballentine Partners increased its Teva Pharmaceuticals (TEVA) stake by 15% in Q2 2026, buying an estimated $49.1K and bringing the position to 11,392 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #668.

Ballentine Partners first reported a position in TEVA in Q2 2017 and has held it in 5 quarters since. The position peaked at $582K in Q2 2017. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Ballentine Partners held 11,392 shares of Teva Pharmaceuticals worth $386K as of Q2 2026.
  • Ballentine Partners bought 1,473 Teva Pharmaceuticals shares in Q2 2026, an estimated $49.1K.
  • Teva Pharmaceuticals made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #668 holding.
  • Ballentine Partners first reported a position in Teva Pharmaceuticals in Q2 2017 and has held it in 5 quarters since.
  • Ballentine Partners's Teva Pharmaceuticals position peaked at $582K in Q2 2017.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.